Quoin Pharmaceuticals Achieves Key Milestone in Topical Rapamycin Program

Quoin Pharmaceuticals shares are trading higher after the company announced it has achieved target loading concentrations for topical rapamycin in two proprietary delivery technologies, initiating clinical development for high-need conditions.